Influenza A virus H5N1 vaccine - CSL

Drug Profile

Influenza A virus H5N1 vaccine - CSL

Alternative Names: Avian influenza (bird flu) virus vaccine - CSL; CSL-401; CSL444 (Pandemic ISCOMATRIX® Flu); H5N1 aluminium pandemic influenza vaccine - CSL; H5N1 pandemic influenza vaccine - CSL; Panvax

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator CSL
  • Class Influenza A virus H5N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza A virus H5N1 subtype

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-A-virus-H5N1-subtype(Prevention) in New Zealand (Parenteral, Injection)
  • 11 Dec 2008 Launched (CSL 401) for Influenza-A virus H5N1 subtype in Australia (Parenteral); first global launch
  • 11 Dec 2008 Registered (CSL 401) for Influenza-A virus H5N1 subtype in Singapore (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top